How Does Bronchitol Work? Mechanism of Action Explained in Plain English

Bronchitol (inhaled mannitol) is one of the few CF medications whose exact mechanism of action is not fully understood — even the FDA label acknowledges this. But scientists have a clear working theory for how it improves lung function in cystic fibrosis, and the evidence from clinical trials shows it works. Here's the clearest explanation of what mannitol does in CF lungs.

The Core Problem in Cystic Fibrosis Lungs

Cystic fibrosis is caused by mutations in the CFTR gene, which encodes a protein that regulates the movement of salt (chloride) and water across cell membranes. When CFTR doesn't work properly, the airway surface becomes dehydrated — the thin layer of fluid lining the airways (called the airway surface liquid, or ASL) shrinks. Without adequate ASL, the hair-like cilia that normally sweep mucus out of the lungs can't function properly.

The result: thick, sticky mucus accumulates in the airways, blocking airflow, trapping bacteria, and causing chronic lung infections and progressive damage over time.

How Mannitol Addresses This: Osmotic Action

Mannitol is a small sugar alcohol molecule with a strong osmotic pull — it attracts water. When mannitol is inhaled as a dry powder and deposited on the airway surface, it creates an osmotic gradient: the airway surface now has a higher concentration of solutes than the surrounding tissues, and water is drawn across the airway epithelium into the airway surface by osmosis.

This rehydration of the airway surface liquid has two key effects:

Mucus hydration: The thick, dry mucus absorbs the water and becomes thinner and less viscous — easier to move and cough out

Improved mucociliary clearance: With more fluid on the airway surface, the cilia regain some ability to move the hydrated mucus up and out of the airways (a process called mucociliary clearance)

The net result is that more mucus is cleared from the airways, which reduces obstruction, decreases the risk of infection, and improves the patient's ability to breathe.

Why the Exact Mechanism Is Listed as "Unknown"

The Bronchitol prescribing information states: "The precise mechanism of action of BRONCHITOL in improving pulmonary function in cystic fibrosis patients is unknown." This might seem surprising given the explanation above, but it's a regulatory statement. It means that while the osmotic theory is well-supported and widely accepted, it hasn't been definitively proven in human clinical mechanistic studies to the FDA's standard for a confirmed mechanism claim.

What is conclusively established is that Bronchitol improves FEV1 in CF patients — two of three Phase 3 trials showed statistically significant FEV1 improvement, and one trial showed a 35.4% reduction in pulmonary exacerbations.

How Bronchitol Differs from Pulmozyme (Dornase Alfa)

Both Bronchitol and Pulmozyme (dornase alfa) are mucolytics used in CF, but they work by completely different mechanisms:

Bronchitol (mannitol): Osmotic agent — hydrates the airway surface, making mucus thinner

Pulmozyme (dornase alfa): Enzymatic mucolytic — acts as molecular scissors, cutting the long strands of DNA from white blood cells that make CF mucus unusually thick and viscous

Because they work differently, Bronchitol can be used alongside Pulmozyme in a comprehensive CF treatment regimen. However, they cannot be used concurrently with inhaled hypertonic saline, which works by the same osmotic mechanism as Bronchitol.

How Bronchitol Differs from CFTR Modulators Like Trikafta

CFTR modulators like Trikafta (elexacaftor/tezacaftor/ivacaftor) work at a completely different level. Instead of addressing mucus that's already been produced, CFTR modulators help fix the underlying protein defect — they help the mutated CFTR protein fold and function more normally, reducing the production of abnormally thick mucus in the first place.

Bronchitol addresses the downstream problem (thick mucus already in the airways), while CFTR modulators address the upstream problem (the protein defect causing the thick mucus). For eligible patients, the two approaches can be complementary.

What the Clinical Evidence Shows

Bronchitol was evaluated in three Phase 3 randomized clinical trials involving 761 adult CF patients. Results showed:

Trial 1 (NCT02134353): 400 mg twice daily produced statistically significant improvement in FEV1 compared to 50 mg control over 26 weeks

Trial 2 (NCT00446680): Significant FEV1 improvement of 6.5% vs 2.4% in placebo group, plus a 35.4% reduction in pulmonary exacerbations

Improvements in FEV1 were maintained for up to 52 weeks in open-label extension phases

For a full overview of Bronchitol, see: What Is Bronchitol? Uses, Dosage, and What You Need to Know in 2026.

For side effects information, see: Bronchitol Side Effects: What to Expect and When to Call Your Doctor.